{
  "model": "chatgpt-gpt-5.3-codex",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/chatgpt-gpt-5-3-codex-tumor-vaccine-ici-run-1",
  "success": true,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": true,
  "durationMs": 72596,
  "agentCostUsd": 0.059133500000000006,
  "graderCostUsd": 0.01440425,
  "totalCostUsd": 0.07353775000000001,
  "agentUsage": {
    "promptTokens": 18310,
    "cachedTokens": 4608,
    "responseTokens": 3402,
    "thinkingTokens": 741,
    "totalTokens": 22453
  },
  "graderUsage": {
    "promptTokens": 4079,
    "cachedTokens": 0,
    "responseTokens": 312,
    "thinkingTokens": 207,
    "totalTokens": 4598
  },
  "totalUsage": {
    "promptTokens": 22389,
    "cachedTokens": 4608,
    "responseTokens": 3714,
    "thinkingTokens": 948,
    "totalTokens": 27051
  },
  "modelVersions": [
    "chatgpt-gpt-5.3-codex"
  ],
  "agentFinalText": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination create an interferon-rich tumor state that improves sensitivity to anti-PD-L1 immune checkpoint blockade?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combination\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled repeat-experiment mouse cohort used to evaluate intratumoral mRNA vaccine with anti-PD-L1 combination efficacy.\"\n    },\n    {\n      \"id\": \"mouse-matched-controls\",\n      \"label\": \"Mouse matched control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched mouse controls covering vaccine-only, ICI-only, and vehicle conditions for comparison against combination therapy effects.\"\n    },\n    {\n      \"id\": \"human-retrospective-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients total\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment and stratified by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination before or around ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, used as comparator for outcomes under ICI.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display in tumors versus comparator.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison under ICI\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"Vaccinated subgroup versus unvaccinated subgroup\",\n      \"interpretation\": \"In the retrospective cohort, prior vaccination status was associated with improved survival under ICI treatment.\",\n      \"evidence_line_refs\": [\"L30\", \"L49\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors showed marked induction of type I interferon response after mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"PD-L1 pathway activity increased, supporting a rationale for checkpoint-blockade combination strategies.\",\n      \"evidence_line_refs\": [\"L32\", \"L45\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Immune infiltration increased with combination therapy compared with baseline/comparator settings.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination induces an interferon-linked tumor state and broadens antigen presentation pathways.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems, so magnitude and consistency may vary across contexts.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The therapeutic rationale is specifically for combining intratumoral mRNA vaccination with checkpoint blockade rather than either monotherapy alone.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"- Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n          \"line_ref\": \"L36\"\n        },\n        {\n          \"quote\": \"- ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n          \"line_ref\": \"L37\"\n        }\n      ],\n      \"caveat\": \"Mouse efficacy may not translate directly to all human tumors, and control performance can depend on baseline tumor immunogenicity.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"In metastatic patients receiving ICI, prior SARS-CoV-2 mRNA vaccination status was associated with better survival outcomes.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"Because the human cohort is retrospective and non-randomized with heterogeneous timing and histories, this supports association rather than definitive causality.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Observed sensitization depends on mRNA cargo and intact type I interferon signaling, based on perturbation controls.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n          \"line_ref\": \"L38\"\n        },\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"These controls support mechanism in tested systems, but pathway dependence may differ across tumor types and clinical settings.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"mRNA tumor priming may help checkpoint therapy, but human evidence is still observational\",\n  \"plain_language_summary\": \"This study tested whether injecting an mRNA vaccine directly into tumors could make immune checkpoint drugs work better. In mouse models, the combination of intratumoral mRNA vaccination plus anti-PD-L1 showed stronger immune activation, including higher interferon signaling, broader antigen display, and more CD8+ T-cell presence. The paper also reports a retrospective analysis of metastatic patients on checkpoint inhibitors, where previously vaccinated patients had better survival statistics (p=0.01). However, the human data do not prove cause and effect because the comparison was non-randomized and clinically heterogeneous. Important control findings temper the conclusion: vaccine-only treatment did not give durable control in non-immunogenic models, ICI-only activity was limited in low-immunogenic settings, lipid particles without mRNA did not reproduce sensitization, and blocking IFNAR1 removed the sensitization benefit.\",\n  \"what_is_new\": [\n    \"The study links intratumoral mRNA delivery to a broader tumor immunopeptidome and expanded MHC-I peptide presentation.\",\n    \"It proposes a stepwise mechanism connecting type I interferon induction to improved checkpoint-blockade susceptibility.\",\n    \"It combines preclinical combination-therapy data with a real-world retrospective metastatic ICI cohort stratified by vaccination status.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human cohort was retrospective and non-randomized, so confounding factors may explain part of the survival difference.\",\n    \"Vaccination timing relative to ICI start varied, and mixed tumor types plus prior-treatment heterogeneity limit causal interpretation.\",\n    \"Control results show boundary conditions: vaccine-only and ICI-only arms were insufficient in some settings, so benefit is context dependent.\",\n    \"Mouse-model mechanistic and efficacy signals may not transfer uniformly to all human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A drug that releases molecular brakes on T cells, helping the immune system attack cancer cells more effectively.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Delivered directly into a tumor rather than given systemically through the bloodstream.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides displayed by cells that immune cells can inspect to detect abnormal or tumor-associated proteins.\"\n    },\n    {\n      \"term\": \"Type I interferon signaling\",\n      \"definition\": \"An innate immune response pathway that can boost antigen processing and strengthen anti-tumor immune visibility.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will prospective randomized trials confirm that this strategy improves patient outcomes beyond standard checkpoint therapy?\",\n    \"Which tumor types and baseline immune states are most likely to benefit from intratumoral mRNA priming?\",\n    \"What vaccination timing and dosing schedule relative to ICI initiation gives the best risk-benefit balance?\",\n    \"Can biomarkers such as interferon-response scores predict who should receive this combination approach?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-19T19:48:11.827Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-19T19:48:13.918Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-19T19:48:13.918Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-19T19:48:16.549Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-19T19:48:16.549Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-19T19:48:16.549Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-19T19:48:16.549Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-19T19:49:05.664Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-19T19:49:05.664Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-19T19:49:05.664Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-19T19:49:05.664Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "value": {
      "verdict": "pass",
      "scores": {
        "faithfulness": 4,
        "coverage": 5,
        "usefulness": 5
      },
      "critical_issues": [
        "Some evidence entries in claim_audit.json use report summaries as “quotes” (e.g., L42–L46) rather than verbatim findings; this is still grounded but could mislead downstream users expecting literal quotations.",
        "In quantitative_findings.json (Q03), the inclusion of L49 as an evidence line reference is not directly supporting the p-value/result (it is a caveat about non-randomization). The core quantitative evidence is correctly at L30."
      ],
      "summary": "Across the JSON files, the study type, cohorts (mouse n=78/84; human n=130 with 43 vaccinated/87 unvaccinated), key quantitative results (immunopeptidome 62.3% vs 37.3%; MHC-I 40.6% vs 20.6%; p=0.01 survival association; IFN score 3.1 vs 1.0; PD-L1 2.4x; CD8 density 1.8x), mechanistic narrative, and the major caveats (retrospective/non-randomized human data, timing heterogeneity, tumor-type mix, translation limits) are accurately represented without fabricated numbers or overstated causal claims"
    }
  }
}
